Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, Wagner JE, Verneris MR.

Biol Blood Marrow Transplant. 2019 May;25(5):883-890. doi: 10.1016/j.bbmt.2019.01.003. Epub 2019 Jan 6.

PMID:
30625388
2.

Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.

Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR, Hogan WJ, Porrata LF, Holtan SG.

Biol Blood Marrow Transplant. 2012 Apr;18(4):600-7. doi: 10.1016/j.bbmt.2011.08.007. Epub 2011 Aug 16.

3.

Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.

DeCook LJ, Thoma M, Huneke T, Johnson ND, Wiegand RA, Patnaik MM, Litzow MR, Hogan WJ, Porrata LF, Holtan SG.

Bone Marrow Transplant. 2013 May;48(5):708-14. doi: 10.1038/bmt.2012.211. Epub 2012 Oct 29.

PMID:
23103674
4.

Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.

Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2008 Mar;14(3):282-9. doi: 10.1016/j.bbmt.2007.12.488.

5.

Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.

Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ.

Biol Blood Marrow Transplant. 2009 May;15(5):564-73. doi: 10.1016/j.bbmt.2009.01.011. Epub 2009 Mar 9.

6.

The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.

Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V.

Haematologica. 2008 Dec;93(12):1852-8. doi: 10.3324/haematol.13033. Epub 2008 Oct 22.

7.

Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant.

Thoma MD, Glejf J, Jacob E, Huneke TJ, DeCook LJ, Johnson ND, Patnaik MM, Litzow MR, Hogan WJ, Newell LF, Chandran R, Porrata LF, Holtan SG.

BMC Hematol. 2014 Sep 1;14(1):14. doi: 10.1186/2052-1839-14-14. eCollection 2014.

8.

Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.

Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ.

J Clin Oncol. 2009 Aug 1;27(22):3634-41. doi: 10.1200/JCO.2008.20.2960. Epub 2009 Jul 6.

9.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

10.

Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning.

Tang L, Wang N, Xing C, Zhuang Q, Liang B, Sun L, Chen Y, Qian Y, Shen Z, Jiang S, Yu K, Feng J.

Leuk Res. 2018 Jun;69:60-65. doi: 10.1016/j.leukres.2018.04.006. Epub 2018 Apr 11.

PMID:
29660493
11.

Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.

Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1327-34. doi: 10.1016/j.bbmt.2011.01.007. Epub 2011 Jan 11.

12.

Phagocytic activity of monocytes, their subpopulations and granulocytes during post-transplant adverse events after hematopoietic stem cell transplantation.

Döring M, Cabanillas Stanchi KM, Erbacher A, Haufe S, Schwarze CP, Handgretinger R, Hofbeck M, Kerst G.

Immunobiology. 2015 May;220(5):605-13. doi: 10.1016/j.imbio.2014.12.002. Epub 2014 Dec 15.

PMID:
25541241
13.

Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.

van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A.

Haematologica. 2016 May;101(5):634-43. doi: 10.3324/haematol.2015.138594. Epub 2016 Feb 11.

14.

Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma.

Galvez-Silva J, Maher OM, Park M, Liu D, Hernandez F, Tewari P, Nieto Y.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1276-1281. doi: 10.1016/j.bbmt.2017.04.013. Epub 2017 Apr 20.

15.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.

Biol Blood Marrow Transplant. 2017 Jun;23(6):971-979. doi: 10.1016/j.bbmt.2017.03.014. Epub 2017 Mar 10.

16.

Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).

Gooptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS.

Biol Blood Marrow Transplant. 2019 Jul 2. pii: S1083-8791(19)30413-6. doi: 10.1016/j.bbmt.2019.06.029. [Epub ahead of print]

PMID:
31271885
17.

Immunosuppression and monocyte subsets.

Rogacev KS, Zawada AM, Hundsdorfer J, Achenbach M, Held G, Fliser D, Heine GH.

Nephrol Dial Transplant. 2015 Jan;30(1):143-53. doi: 10.1093/ndt/gfu315. Epub 2014 Oct 13.

PMID:
25313167
18.

[Single center comparative analysis of hematopoietic cell transplantation from alternated donor in patients with hematologic malignancies].

Wang J, Zhou J, Zheng HF, Wang PF, Fu CC.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Feb;23(1):159-65. doi: 10.7534/j.issn.1009-2137.2015.01.031. Chinese.

PMID:
25687066
19.

[A new multi-factor risk score system for predicting the outcome after allogenic hematopoietic stem cell transplantation].

Liu J, Xu LP, Liu DH, Liu KY, Wang Y, Chen YH, Han W, Chen H, Wang FR, Zhang XH, Zhao XY, Zhao XS, Lyu M, Chang YJ, Huang XJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):117-24. doi: 10.7534/j.issn.1009-2137.2014.01.024. Chinese.

PMID:
24598663
20.

Prognostic significance of preoperative absolute peripheral monocyte count in esophageal squamous cell carcinoma.

Han L, Jia Y, Song Q, Wang N, Wang J, Bai B, Chen X, Wang C, Cheng Y.

Dis Esophagus. 2016 Oct;29(7):740-746. doi: 10.1111/dote.12401. Epub 2015 Aug 28.

PMID:
26316375

Supplemental Content

Support Center